Citius Pharmaceuticals, Inc. — Form 8-K
Filed November 4, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Citius Oncology presented exploratory quality-of-life data from Study 302 at the EORTC-CLTG 2026 Annual Meeting in Berlin (October 8–10, 2026). Among 25 responders, Skindex-29 scores improved 5.38–13.69 points vs. non-responders; 32% of 41 heavily pretreated patients with baseline itch ≥20 mm achieved ≥20 mm decrease sustained ≥4 weeks. LYMPHIR was FDA-approved and launched in December 2025; the estimated initial CTCL market exceeds $400M. The analyses were descriptive, not statistically powered, and not included in prescribing information.
Why this rating
Routine post-launch clinical data presentation supporting approved product already commercialized; exploratory QoL findings are supportive but uncontrolled, unpowered; immaterial to $11.4M market-cap company operating as going concern with substantial funding needs.
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.